H. Richards

1.4k total citations
44 papers, 1.1k citations indexed

About

H. Richards is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, H. Richards has authored 44 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Rheumatology, 26 papers in Immunology and 12 papers in Hematology. Recurrent topics in H. Richards's work include Rheumatoid Arthritis Research and Therapies (28 papers), Spondyloarthritis Studies and Treatments (27 papers) and Psoriasis: Treatment and Pathogenesis (15 papers). H. Richards is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (28 papers), Spondyloarthritis Studies and Treatments (27 papers) and Psoriasis: Treatment and Pathogenesis (15 papers). H. Richards collaborates with scholars based in United States, Switzerland and United Kingdom. H. Richards's co-authors include Westley H. Reeves, Marco Tucci, Franco Silvestris, Minoru Satoh, Pille Konno, Bárður Sigurgeirsson, Kim Papp, Donald R Baker, Masatoshi Abe and Sibylle Haemmerle and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Immunology and Environmental Health Perspectives.

In The Last Decade

H. Richards

44 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. Richards United States	15	864	623	187	184	160	44	1.1k
A.B. Gottlieb United States	9	1.1k 1.3×	385 0.6×	232 1.2×	539 2.9×	110 0.7×	35	1.4k
L T Dooley United States	5	1.1k 1.3×	849 1.4×	502 2.7×	376 2.0×	63 0.4×	5	1.5k
Nadine Davelaar Netherlands	12	460 0.5×	274 0.4×	112 0.6×	69 0.4×	79 0.5×	24	725
Georg Stummvoll Austria	17	544 0.6×	286 0.5×	56 0.3×	37 0.2×	131 0.8×	32	944
Alessandra Cannizzaro Italy	11	396 0.5×	365 0.6×	161 0.9×	68 0.4×	127 0.8×	17	729
Takahiko Sugihara Japan	16	279 0.3×	488 0.8×	166 0.9×	42 0.2×	227 1.4×	72	1.0k
Yichuan Xia United States	4	637 0.7×	156 0.3×	99 0.5×	338 1.8×	63 0.4×	6	892
Florence Ida Hsu United States	11	269 0.3×	217 0.3×	66 0.4×	156 0.8×	65 0.4×	26	985
Ceara AE Walsh Ireland	10	198 0.2×	394 0.6×	158 0.8×	57 0.3×	82 0.5×	11	717
Yonsu Son Japan	16	264 0.3×	412 0.7×	162 0.9×	33 0.2×	80 0.5×	49	712

Countries citing papers authored by H. Richards

Since Specialization

Citations

This map shows the geographic impact of H. Richards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Richards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Richards more than expected).

Fields of papers citing papers by H. Richards

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Richards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Richards. The network helps show where H. Richards may publish in the future.

Co-authorship network of co-authors of H. Richards

This figure shows the co-authorship network connecting the top 25 collaborators of H. Richards. A scholar is included among the top collaborators of H. Richards based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Richards. H. Richards is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baraliakos, Xenofon, Désirée van der Heijde, Pedro Machado, et al.. (2023). POS1115 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SUBGROUP ANALYSES BY BASELINE SYNDESMOPHYTES AND C-REACTIVE PROTEIN STATUS. 882.1–883. 2 indexed citations

Baraliakos, Xenofon, Mikkel Østergaard, Denis Poddubnyy, et al.. (2023). OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY. Annals of the Rheumatic Diseases. 82. 38–40. 4 indexed citations

Braun, Jürgen, Ricardo Blanco, Eva Dokoupilová, et al.. (2020). OP0106 SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY. Annals of the Rheumatic Diseases. 79. 69–70. 5 indexed citations

Deodhar, Atul, Iain B. McInnes, Xenofon Baraliakos, et al.. (2020). FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES. Annals of the Rheumatic Diseases. 79. 722–722. 4 indexed citations

Braun, Jürgen, Hildrun Haibel, Manouk de Hooge, et al.. (2019). Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Research & Therapy. 21(1). 142–142. 31 indexed citations

Braun, Joseph M., Hildrun Haibel, Manouk de Hooge, et al.. (2018). SAT0259 Low rate of spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Annals of the Rheumatic Diseases. 77. 992–993. 3 indexed citations

Marzo‐Ortega, Helena, Joachim Sieper, Alan Kivitz, et al.. (2017). Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. Arthritis Care & Research. 69(7). 1020–1029. 76 indexed citations

Maksymowych, Walter P., Vibeke Strand, Peter Nash, et al.. (2016). Secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus adalimumab Using a matching-adjusted indirect comparison. Clinical and Experimental Rheumatology. 34(4). 782–782. 4 indexed citations

Maksymowych, Walter P., Vibeke Strand, Dominique Baeten, et al.. (2016). OP0114 Secukinumab for The Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Adalimumab Using A Matching-Adjusted Indirect Comparison. Annals of the Rheumatic Diseases. 75. 98–98. 2 indexed citations

10.

Braun, Jürgen, Xenofon Baraliakos, Atul Deodhar, et al.. (2016). OP0001 Effect of Secukinumab, An Interleukin-17a Inhibitor, on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of The Phase 3 Study, Measure 1. Annals of the Rheumatic Diseases. 75. 52–52. 11 indexed citations

11.

McInnes, Iain B., B. W. Kirkham, Arthur Kavanaugh, et al.. (2015). Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Journal of Investigative Dermatology. 135. 2 indexed citations

12.

McInnes, Iain B., Philip J. Mease, Bruce Kirkham, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing. Data Archiving and Networked Services (DANS). 66(12). 3529–3529. 19 indexed citations

13.

Landewé, Robert, Iain B. McInnes, Philip G. Conaghan, et al.. (2014). Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study. Data Archiving and Networked Services (DANS). 66. 42–43. 16 indexed citations

14.

Papp, Kim, Richard G. Langley, Bárður Sigurgeirsson, et al.. (2012). Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. British Journal of Dermatology. 168(2). 412–421. 296 indexed citations

15.

Richards, H., Elizabeth A. Reap, Melody Shaw, et al.. (2000). B Cell Subsets in Pristane-induced Autoimmunity. Current topics in microbiology and immunology. 252. 201–207. 6 indexed citations

16.

Richards, H., et al.. (1999). Induction of B Cell Autoimmunity by Pristane. Current topics in microbiology and immunology. 246. 387–393. 6 indexed citations

17.

Satoh, Minoru, H. Richards, Hideo Yoshida, et al.. (1999). Immunopathogenesis of environmentally induced lupus in mice.. Environmental Health Perspectives. 107(suppl 5). 723–727. 30 indexed citations

18.

Richards, H., et al.. (1999). Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clinical & Experimental Immunology. 115(3). 547–553. 33 indexed citations

19.

Satoh, Minoru, et al.. (1997). Human anti-nuclear ribonucleoprotein antigen autoimmune sera contain a novel subset of autoantibodies that stabilizes the molecular interaction of U1RNP-C protein with the Sm core proteins. The Journal of Immunology. 158(10). 5017–5025. 21 indexed citations

20.

Satoh, Minoru, et al.. (1996). Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein.. Journal of Clinical Investigation. 97(11). 2619–2626. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact